{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-250724","form_type":"8-K","ticker":"NUVL","cik":"0001861560","company_name":"Nuvalent, Inc.","filed_at":"2023-10-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:31.166058+00:00","generated_at":"2026-06-10T05:00:26.727030+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Nuvalent reports NVL-655 Phase 1 data: 45% ORR in evaluable ALK+ NSCLC patients","bullets":["57 patients received 15–200 mg once daily; 51% had baseline CNS metastases; 77% post-lorlatinib.","ORR 45% (15/33) in evaluable ALK+ NSCLC; 65% (11/17) in patients with ALK resistance mutations.","41% ORR (12/29) in post-lorlatinib patients, including those with compound resistance mutations.","No MTD identified; most common TRAEs: nausea (12%), transaminase elevation (12%), fatigue (9%).","Updated data to be presented Oct 13 at AACR-NCI-EORTC; company to host conference call that day."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-250724","json":"https://secwatch.observer/filing/0001193125-23-250724.json","markdown":"https://secwatch.observer/filing/0001193125-23-250724.md","text":"https://secwatch.observer/filing/0001193125-23-250724.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1861560/000119312523250724/0001193125-23-250724-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1861560/000119312523250724/d541910d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-10T05:00:26.727030+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}